5,000 Shares in Doximity, Inc. (NASDAQ:DOCS) Acquired by one8zero8 LLC

one8zero8 LLC acquired a new position in shares of Doximity, Inc. (NASDAQ:DOCSFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 5,000 shares of the company’s stock, valued at approximately $267,000.

Several other large investors also recently added to or reduced their stakes in DOCS. Shaker Investments LLC OH purchased a new position in shares of Doximity during the fourth quarter valued at $559,000. Penserra Capital Management LLC acquired a new stake in Doximity during the 3rd quarter worth about $2,384,000. Principal Financial Group Inc. grew its stake in Doximity by 1.5% during the 4th quarter. Principal Financial Group Inc. now owns 293,974 shares of the company’s stock valued at $15,695,000 after acquiring an additional 4,282 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new position in shares of Doximity in the 4th quarter valued at about $362,000. Finally, Stratos Wealth Partners LTD. purchased a new stake in shares of Doximity in the fourth quarter worth approximately $203,000. 87.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on DOCS shares. Piper Sandler raised shares of Doximity from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $31.00 to $78.00 in a research report on Friday, February 7th. Raymond James restated an “outperform” rating and set a $83.00 price target (up from $65.00) on shares of Doximity in a report on Friday, February 7th. Leerink Partners upgraded Doximity from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $60.00 to $90.00 in a report on Friday, February 7th. Canaccord Genuity Group boosted their target price on Doximity from $60.00 to $71.00 and gave the company a “hold” rating in a research note on Friday, February 7th. Finally, Stephens started coverage on Doximity in a research note on Friday, December 20th. They set an “equal weight” rating and a $55.00 price target for the company. Eleven equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $64.22.

View Our Latest Stock Analysis on Doximity

Doximity Price Performance

DOCS stock opened at $63.33 on Monday. The stock has a market capitalization of $11.82 billion, a price-to-earnings ratio of 63.33, a price-to-earnings-growth ratio of 4.10 and a beta of 1.34. The company has a 50-day moving average of $63.63 and a two-hundred day moving average of $52.72. Doximity, Inc. has a 52-week low of $22.96 and a 52-week high of $85.21.

Insider Buying and Selling

In other Doximity news, Director Timothy S. Cabral sold 20,000 shares of Doximity stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $57.62, for a total value of $1,152,400.00. Following the transaction, the director now directly owns 6,360 shares of the company’s stock, valued at $366,463.20. The trade was a 75.87 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 37.40% of the stock is owned by insiders.

Doximity Profile

(Free Report)

Doximity, Inc operates a cloud-based digital platform for medical professionals in the United States. The company's platform provides its members with tools built for medical professionals, enabling them to collaborate with their colleagues, coordinate patient care, conduct virtual patient visits, stay up to date with the latest medical news and research, and manage their careers.

Featured Articles

Institutional Ownership by Quarter for Doximity (NASDAQ:DOCS)

Receive News & Ratings for Doximity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Doximity and related companies with MarketBeat.com's FREE daily email newsletter.